Glen S. Markowitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Glen S. Markowitz has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
V D D'Agati
6 shared publicationsJai Radhakrishnan
Nephrology Division, Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, New York, USA
5 shared publicationsVivette D. D'AGati
Department of Pathology College of Physicians and Surgeons Columbia University New York New York
4 shared publicationsVivette D. D'Agati
4 shared publicationsA M Valeri
3 shared publicationsG B Appel
3 shared publications
Latest Publications
- Open Access
- 24 July 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (1) , 16-18
Increased prevalence of acute interstitial nephritis: more disease or simply more detection?
Acute interstitial nephritis (AIN) is the second leading cause of acute, intrinsic kidney disease [1]. Unlike acute tubular necrosis, the most common cause of intrinsic kidney injury, AIN is known to have a high potential for reversibility if identified early [2]. The diagnosis of AIN is often made empirically based on the clinical presentation (e.g. a case of acute kidney injury (AKI) accompanied by a history of rash and fever, peripheral eosinophilia and a urine devoid of protein), yet a true diagnosis of AIN can only be established by a renal biopsy. Indeed, because AIN most commonly occurs in the absence of supportive clinical or laboratory findings, the importance of kidney biopsy to firmly diagnose AIN as the cause of AKI cannot be understated. A biopsy not only confirms the pathologic diagnosis but can also provide information on the severity of the injury, activity versus chronicity of the lesion, and the presence of other significant glomerular or vascular abnormalities that may influence treatment decisions [3].
- 24 July 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (1) , 16-18
Open AccessIncreased prevalence of acute interstitial nephritis: more disease or simply more detection?
Acute interstitial nephritis (AIN) is the second leading cause of acute, intrinsic kidney disease [1]. Unlike acute tubular necrosis, the most common cause of intrinsic kidney injury, AIN is known to have a high potential for reversibility if identified early [2]. The diagnosis of AIN is often made empirically based on the clinical presentation (e.g. a case of acute kidney injury (AKI) accompanied by a history of rash and fever, peripheral eosinophilia and a urine devoid of protein), yet a true diagnosis of AIN can only be established by a renal biopsy. Indeed, because AIN most commonly occurs in the absence of supportive clinical or laboratory findings, the importance of kidney biopsy to firmly diagnose AIN as the cause of AKI cannot be understated. A biopsy not only confirms the pathologic diagnosis but can also provide information on the severity of the injury, activity versus chronicity of the lesion, and the presence of other significant glomerular or vascular abnormalities that may influence treatment decisions [3].
- Open Access
- 1 April 2010
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (4) , 607-615
Treatment with IFN-α, -β, or -γ Is Associated with Collapsing Focal Segmental Glomerulosclerosis
Background and objectives: Treatment with IFN is rarely associated with nephrotic syndrome and renal biopsy findings of minimal-change disease or FSGS. Design, setting, participants, & measurements: We report 11 cases of collapsing FSGS that developed during treatment with IFN and improved after discontinuation of therapy. Results: The cohort consists of seven women and four men with a mean age of 48.2 yr. Ten of the 11 patients were black. Six patients were receiving IFN-α for hepatitis C virus infection (n = 5) or malignant melanoma (n = 1), three were receiving IFN-β for multiple sclerosis, and two were treated with IFN-γ for idiopathic pulmonary fibrosis. After a mean and median duration of therapy of 4.0 and 12.6 months, respectively, patients presented with acute renal failure (mean creatinine 3.5 mg/dl) and nephrotic-range proteinuria (mean 24-hour urine protein 9.7 g). Renal biopsy revealed collapsing FSGS with extensive foot process effacement and many endothelial tubuloreticular inclusions. Follow-up was available for 10 patients, all of whom discontinued IFN. At a mean of 23.6 months, nine of 10 patients had improvement in renal function, including one with complete remission and two with partial remission. Among the seven patients with available data, mean proteinuria declined from 9.9 to 3.0 g/d. Four of the seven patients were treated with immunosuppression, and there was no detectable benefit. Conclusions: Collapsing FSGS may occur after treatment with IFN-α, -β, or -γ and is typically accompanied by the ultrastructural finding of endothelial tubuloreticular inclusions. Optimal therapy includes discontinuation of IFN.
- 1 April 2010
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (4) , 607-615
Open AccessTreatment with IFN-α, -β, or -γ Is Associated with Collapsing Focal Segmental Glomerulosclerosis
Background and objectives: Treatment with IFN is rarely associated with nephrotic syndrome and renal biopsy findings of minimal-change disease or FSGS. Design, setting, participants, & measurements: We report 11 cases of collapsing FSGS that developed during treatment with IFN and improved after discontinuation of therapy. Results: The cohort consists of seven women and four men with a mean age of 48.2 yr. Ten of the 11 patients were black. Six patients were receiving IFN-α for hepatitis C virus infection (n = 5) or malignant melanoma (n = 1), three were receiving IFN-β for multiple sclerosis, and two were treated with IFN-γ for idiopathic pulmonary fibrosis. After a mean and median duration of therapy of 4.0 and 12.6 months, respectively, patients presented with acute renal failure (mean creatinine 3.5 mg/dl) and nephrotic-range proteinuria (mean 24-hour urine protein 9.7 g). Renal biopsy revealed collapsing FSGS with extensive foot process effacement and many endothelial tubuloreticular inclusions. Follow-up was available for 10 patients, all of whom discontinued IFN. At a mean of 23.6 months, nine of 10 patients had improvement in renal function, including one with complete remission and two with partial remission. Among the seven patients with available data, mean proteinuria declined from 9.9 to 3.0 g/d. Four of the seven patients were treated with immunosuppression, and there was no detectable benefit. Conclusions: Collapsing FSGS may occur after treatment with IFN-α, -β, or -γ and is typically accompanied by the ultrastructural finding of endothelial tubuloreticular inclusions. Optimal therapy includes discontinuation of IFN.
- 1 November 2009
- Published by Elsevier in Kidney International
- Vol. 76 (10) , 1027-1034
Acute phosphate nephropathy
- 1 November 2009
- Published by Elsevier in Kidney International
- Vol. 76 (10) , 1027-1034
Acute phosphate nephropathy
- 1 October 2009
- Published by Elsevier in Kidney International
- Vol. 76 (7) , 792-797
Light chain proximal tubulopathy
- 1 October 2009
- Published by Elsevier in Kidney International
- Vol. 76 (7) , 792-797
Light chain proximal tubulopathy
- 1 May 2009
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 18 (3) , 220-225
Classification of lupus nephritis
Lupus nephritis manifests as diverse patterns of immune complex-mediated renal disease affecting glomerular, tubulointerstitial, and vascular compartments. This review will focus on the most recent classification, the ‘International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Classification of Lupus Nephritis’, and will briefly discuss other types of renal disease seen in patients with systemic lupus erythematosus. The ISN/RPS 2003 Classification of lupus nephritis includes multiple changes from its predecessors, most notably removal of the subclasses of lupus nephritis class V (i.e. Va–Vd), elimination of the normal category (WHO class I), clearer definitions for all classes, a standard approach to sclerotic glomeruli, and the division of lupus nephritis class IV into subcategories based on whether the endocapillary involvement is predominantly segmental (lupus nephritis IV-S) or global (lupus nephritis IV-G). These changes have led to a higher level of interobserver reproducibility and a significant increase in the number of cases of class IV, with a reciprocal decline in lupus nephritis class III and lupus nephritis class V. Multiple studies have found that lupus nephritis class IV-S has similar or better outcomes than lupus nephritis class IV-G. The ISN/RPS 2003 classification of lupus nephritis is gaining widespread acceptance and appears to be achieving its goals of reproducibility and clinical relevance.
- 1 May 2009
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 18 (3) , 220-225
Classification of lupus nephritis
Lupus nephritis manifests as diverse patterns of immune complex-mediated renal disease affecting glomerular, tubulointerstitial, and vascular compartments. This review will focus on the most recent classification, the ‘International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Classification of Lupus Nephritis’, and will briefly discuss other types of renal disease seen in patients with systemic lupus erythematosus. The ISN/RPS 2003 Classification of lupus nephritis includes multiple changes from its predecessors, most notably removal of the subclasses of lupus nephritis class V (i.e. Va–Vd), elimination of the normal category (WHO class I), clearer definitions for all classes, a standard approach to sclerotic glomeruli, and the division of lupus nephritis class IV into subcategories based on whether the endocapillary involvement is predominantly segmental (lupus nephritis IV-S) or global (lupus nephritis IV-G). These changes have led to a higher level of interobserver reproducibility and a significant increase in the number of cases of class IV, with a reciprocal decline in lupus nephritis class III and lupus nephritis class V. Multiple studies have found that lupus nephritis class IV-S has similar or better outcomes than lupus nephritis class IV-G. The ISN/RPS 2003 classification of lupus nephritis is gaining widespread acceptance and appears to be achieving its goals of reproducibility and clinical relevance.
- 1 April 2009
- Published by Elsevier in Kidney International
- Vol. 75 (8) , 856-859
A case of nephrocalcinosis
- 1 April 2009
- Published by Elsevier in Kidney International
- Vol. 75 (8) , 856-859
A case of nephrocalcinosis
- 1 December 2008
- Published by Elsevier in Kidney International
- Vol. 74 (11) , 1385-1393
Bisphosphonate nephrotoxicity
- 1 December 2008
- Published by Elsevier in Kidney International
- Vol. 74 (11) , 1385-1393
Bisphosphonate nephrotoxicity
- 1 March 2007
- Published by Elsevier in Kidney International
- Vol. 71 (6) , 491-495
The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years
- 1 March 2007
- Published by Elsevier in Kidney International
- Vol. 71 (6) , 491-495
The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years
- 1 June 2006
- Published by Elsevier in Kidney International
- Vol. 69 (12) , 2278-2282
An 18-year-old male with hematuria, renal insufficiency, and defective synthesis of type IV collagen
- 1 June 2006
- Published by Elsevier in Kidney International
- Vol. 69 (12) , 2278-2282
An 18-year-old male with hematuria, renal insufficiency, and defective synthesis of type IV collagen
- Open Access
- 1 November 2005
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (11) , 3389-3396
Acute Phosphate Nephropathy following Oral Sodium Phosphate Bowel Purgative
The findings of diffuse tubular injury with abundant tubular calcium phosphate deposits on renal biopsy are referred to as nephrocalcinosis, a condition typically associated with hypercalcemia. During the period from 2000 to 2004, 31 cases of nephrocalcinosis were identified among the 7349 native renal biopsies processed at Columbia University. Among the 31 patients, 21 presented with acute renal failure (ARF), were normocalcemic, and had a history of recent colonoscopy preceded by bowel cleansing with oral sodium phosphate solution (OSPS) or Visicol. Because the precipitant was OSPS rather than hypercalcemia, these cases are best termed acute phosphate nephropathy. The cohort of 21 patients with APhN was predominantly female (81.0%) and white (81.0%), with a mean age of 64.0 yr. Sixteen of the 21 patients had a history of hypertension, 14 (87.5%) of whom were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The mean baseline serum creatinine was 1.0 mg/dl, available within 4 mo of colonoscopy in 19 (90.5%) patients. Patients presented with ARF and a mean creatinine of 3.9 mg/dl at a median of 1 mo after colonoscopy. In a few patients, ARF was discovered within 3 d of colonoscopy, at which time hyperphosphatemia was documented. Patients had minimal proteinuria, normocalcemia, and bland urinary sediment. At follow-up (mean 16.7 mo), four patients had gone on to require permanent hemodialysis. The remaining 17 patients all have developed chronic renal insufficiency (mean serum creatinine, 2.4 mg/dl). Acute phosphate nephropathy is an underrecognized cause of acute and chronic renal failure. Potential etiologic factors include inadequate hydration (while receiving OSPS), increased patient age, a history of hypertension, and concurrent use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
- 1 November 2005
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (11) , 3389-3396
Open AccessAcute Phosphate Nephropathy following Oral Sodium Phosphate Bowel Purgative
The findings of diffuse tubular injury with abundant tubular calcium phosphate deposits on renal biopsy are referred to as nephrocalcinosis, a condition typically associated with hypercalcemia. During the period from 2000 to 2004, 31 cases of nephrocalcinosis were identified among the 7349 native renal biopsies processed at Columbia University. Among the 31 patients, 21 presented with acute renal failure (ARF), were normocalcemic, and had a history of recent colonoscopy preceded by bowel cleansing with oral sodium phosphate solution (OSPS) or Visicol. Because the precipitant was OSPS rather than hypercalcemia, these cases are best termed acute phosphate nephropathy. The cohort of 21 patients with APhN was predominantly female (81.0%) and white (81.0%), with a mean age of 64.0 yr. Sixteen of the 21 patients had a history of hypertension, 14 (87.5%) of whom were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The mean baseline serum creatinine was 1.0 mg/dl, available within 4 mo of colonoscopy in 19 (90.5%) patients. Patients presented with ARF and a mean creatinine of 3.9 mg/dl at a median of 1 mo after colonoscopy. In a few patients, ARF was discovered within 3 d of colonoscopy, at which time hyperphosphatemia was documented. Patients had minimal proteinuria, normocalcemia, and bland urinary sediment. At follow-up (mean 16.7 mo), four patients had gone on to require permanent hemodialysis. The remaining 17 patients all have developed chronic renal insufficiency (mean serum creatinine, 2.4 mg/dl). Acute phosphate nephropathy is an underrecognized cause of acute and chronic renal failure. Potential etiologic factors include inadequate hydration (while receiving OSPS), increased patient age, a history of hypertension, and concurrent use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.